Sloan-kettering Institute for Cancer Research

Peter Besmer

Jochen Buck

Karl Henry Nocka

Malcolm A Moore

Malcolm A S Moore

A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention. This invention provides combination therapies using c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. It also provides methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described. Such an antagonist may also be a small molecule. Antisense nucleic acids to KL as therapeutics are also described. Lastly, compositions and methods are described that take advantage of the role of KL in germ cells, mast cells and melanocytes.

C-kit ligand-based method for expanding peripheral blood cell levels

Compositions comprising c-kit ligand, TNF-.alpha., and a hematopoietic factor are useful to promote the expansion of peripheral blood cells or the expansion and differentiation of hematopoietic progenitor cells.

Use of c-kit ligand with TNF-.alpha. and hematopoietic factors for the

Composition of c-kit ligand, GM-CSF, and TNF-.alpha. and method of use

Method for increasing the level of stem cells in peripheral blood

Compositions of soluble C-kit ligand and hematopoietic factors

Growing community of inventors

New York, NY, United States of America

Peter Besmer